tada, icon, I gave up trying to estimate data release/top-line, etc 6 months ago. I don't care much when it happens. I certainly hope they include as many cases as possible for statistical reasons. Every case helps a bit.
What I really care about is the orchestration of the data release. I don't want to see another June 2013 even though that will create an excellent buying opportunity IMHO.
My best scenarios would be:
- If the topline total sample result is significant at 99% or higher then I think a simple topline would generate real interest.
- If the top line is significant at 95% I would hold off until the key subgroups are analysed e.g rosuvastatin vs atorvastatin, etc.
- If the topline overall data is <95% significant I don't want to see results until the full data set is analysed in depth with all key findings thoroughly understood and I'd like to see a re-estimate of the market potential along with the release.
RVX needs to get control of the agenda and pitch it in the most professional manner with the help of professional communications experts.
Just my simple opinion because if TL<95% but rosuvastatin >99% RVX has an incredible story to tell. If TL<95% panic will set in and nobody will give them credibility for months or until the next set of trials.
GLTA
Toinv
